Skip to content
TrialScanner

NCT04634825

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Phase 2TerminatedMGNXLead

Registry record

Lead sponsor
MacroGenics
Conditions
Head and Neck Cancer; Head and Neck Neoplasms; Head and Neck Squamous Cell Carcinoma
Primary completion
Jul 29, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04634825 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04634825: Enoblituzumab Plus Retifanlim... | TrialScanner